KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Restructuring Costs (2024 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Restructuring Costs for 2 consecutive years, with $8.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Restructuring Costs rose 53.99% to $8.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $26.8 million, a 29.71% increase, with the full-year FY2025 number at $26.8 million, up 29.71% from a year prior.
  • Restructuring Costs was $8.5 million for Q4 2025 at Xenon Pharmaceuticals, up from $6.7 million in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $8.5 million in Q4 2025 to a low of $4.6 million in Q3 2024.